Somatostatin eye drops - BCN Peptides

Drug Profile

Somatostatin eye drops - BCN Peptides

Alternative Names: COLIRIOBCN070660; Somatostatin 0.1% eye drops

Latest Information Update: 07 Oct 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator BCN Peptides
  • Class Antihaemorrhagics; Antineoplastics; Cyclic peptides; Pancreatic hormones; Pituitary hormone release inhibiting hormones
  • Mechanism of Action Corticotropin-releasing-hormone-Inhibitors; Growth hormone releasing factor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase II/III Diabetic retinopathy

Most Recent Events

  • 06 Oct 2017 Initial efficacy and adverse events data from the phase II/III EUROCONDOR trial in Diabetic retinopathy presented at the 53rd Annual Meeting of the European Association for the Study of Diabetes (EASD-2017)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top